Jean-Charles Soria Selected Research

Necrosis

1/2016	Rationale for anti-OX40 cancer immunotherapy.
1/2016	Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).
9/2013	Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
1/2011	An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Charles Soria Research Topics

Disease

243	Neoplasms (Cancer) 10/2023 - 05/2002
121	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 05/2002
55	Lung Neoplasms (Lung Cancer) 12/2023 - 01/2003
18	Neoplasm Metastasis (Metastasis) 12/2022 - 05/2003
18	Disease Progression 01/2020 - 10/2006
14	Breast Neoplasms (Breast Cancer) 01/2020 - 12/2004
13	Adenocarcinoma of Lung 01/2023 - 03/2005
13	Adenocarcinoma 02/2021 - 07/2004
12	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018 - 07/2004
11	Melanoma (Melanoma, Malignant) 12/2022 - 08/2010
11	Fatigue 01/2021 - 02/2013
10	Nausea 01/2019 - 02/2013
10	Carcinoma (Carcinomatosis) 10/2018 - 01/2002
10	Carcinogenesis 09/2011 - 01/2002
7	COVID-19 02/2024 - 01/2020
7	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 02/2010
7	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 06/2010
6	Pneumonia (Pneumonitis) 01/2022 - 09/2009
6	Circulating Neoplastic Cells 01/2020 - 01/2002
6	Thrombocytopenia (Thrombopenia) 10/2018 - 03/2010
6	Diarrhea 01/2018 - 10/2006
6	Vomiting 06/2017 - 03/2013
6	Neutropenia 05/2017 - 03/2008
6	Colorectal Neoplasms (Colorectal Cancer) 08/2014 - 10/2003
5	Exanthema (Rash) 01/2021 - 10/2006
5	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 10/2010
4	Mesothelioma 01/2023 - 09/2009
4	Lymphopenia (Lymphocytopenia) 12/2021 - 01/2016
4	Lymphoma (Lymphomas) 01/2018 - 05/2012
4	Cardiotoxicity 07/2016 - 04/2007
4	Necrosis 01/2016 - 01/2011
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 07/2013 - 08/2003
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 01/2002
3	Genomic Instability 11/2021 - 05/2008
3	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 06/2015
3	Leukemia 01/2019 - 03/2013
3	Anorexia 10/2018 - 02/2013

Drug/Important Bio-Agent (IBA)

50	Biomarkers (Surrogate Marker)IBA 02/2024 - 11/2004
26	Proteins (Proteins, Gene)FDA Link 10/2023 - 09/2004
26	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 09/2006
22	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2005
21	Immune Checkpoint InhibitorsIBA 10/2023 - 02/2014
18	PlatinumIBA 12/2023 - 07/2007
18	ErbB Receptors (EGF Receptor)IBA 11/2018 - 11/2003
14	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2003
14	Monoclonal AntibodiesIBA 10/2019 - 01/2006
14	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 10/2006
13	Bevacizumab (Avastin)FDA Link 11/2017 - 02/2010
10	LigandsIBA 10/2023 - 11/2005
10	pembrolizumabIBA 01/2023 - 05/2015
10	Paclitaxel (Taxol)FDA LinkGeneric 11/2017 - 02/2006
9	AntibodiesIBA 11/2022 - 05/2015
9	Phosphotransferases (Kinase)IBA 10/2021 - 07/2005
9	Carboplatin (JM8)FDA LinkGeneric 10/2021 - 02/2006
9	CrizotinibIBA 04/2017 - 05/2012
9	Telomerase (Telomerase Reverse Transcriptase)IBA 06/2010 - 01/2002
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 12/2009
8	Gemcitabine FDA Link 06/2017 - 07/2007
8	Sorafenib (BAY 43-9006)FDA Link 01/2017 - 08/2009
7	Gefitinib (Iressa)FDA Link 01/2020 - 02/2006
7	Pemetrexed (MTA)FDA Link 11/2017 - 04/2009
6	RNA (Ribonucleic Acid)IBA 10/2023 - 05/2007
6	Everolimus FDA Link 04/2021 - 12/2010
6	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 03/2013
6	Anaplastic Lymphoma KinaseIBA 01/2020 - 11/2016
6	AfatinibIBA 09/2019 - 08/2015
6	Messenger RNA (mRNA)IBA 09/2013 - 09/2002
5	B7-H1 AntigenIBA 01/2022 - 11/2014
5	ParaffinIBA 01/2019 - 09/2011
5	Cyclin-Dependent Kinases (cdk Proteins)IBA 06/2017 - 05/2010
5	Alanine Transaminase (SGPT)IBA 05/2017 - 11/2016
5	EnzymesIBA 02/2013 - 07/2006
4	Immunoconjugates (Immunoconjugate)IBA 10/2023 - 01/2019
4	CytokinesIBA 01/2023 - 01/2011
4	durvalumabIBA 01/2022 - 01/2016
4	NivolumabIBA 01/2022 - 01/2017
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 09/2012
4	Formaldehyde (Formol)FDA Link 01/2019 - 09/2013
4	Vinorelbine (Navelbine)FDA LinkGeneric 01/2019 - 01/2016
4	AlbuminsIBA 01/2018 - 03/2012
4	atezolizumabIBA 01/2018 - 11/2014
4	Angiogenesis InhibitorsIBA 08/2014 - 04/2009
4	Trastuzumab (Herceptin)FDA Link 01/2014 - 12/2010
3	Carcinoembryonic AntigenIBA 10/2023 - 01/2004
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2022 - 03/2012
3	Immunologic Factors (Immunomodulators)IBA 07/2022 - 06/2013
3	InterferonsIBA 01/2022 - 01/2011
3	Antiviral Agents (Antivirals)IBA 01/2022 - 05/2016
3	osimertinibIBA 01/2020 - 11/2018
3	Circulating Tumor DNAIBA 01/2019 - 01/2016
3	rociletinibIBA 11/2018 - 04/2015

Therapy/Procedure

95	Therapeutics 01/2023 - 11/2003
57	Drug Therapy (Chemotherapy) 01/2022 - 03/2003
41	Immunotherapy 01/2023 - 02/2011
20	Adjuvant Chemotherapy 01/2023 - 01/2004
12	Precision Medicine 01/2022 - 01/2011
11	Radiotherapy 11/2020 - 10/2004
8	Chemoprevention 05/2007 - 01/2002
5	Molecular Targeted Therapy 01/2016 - 12/2003
3	Induction Chemotherapy 01/2018 - 07/2007